Biotech / Medical
TTPH, Tetraphase Pharmaceuticals
An SI Board Since January 2016
Posts SubjectMarks Bans Symbol
80 22 0 TTPH
Emcee:  scaram(o)uche Type:  Moderated
Tetraphase has hit a snag, failing inferiority testing with an antibiotic at phase III. The company should be considered as having two phase I clinical trial programs, with one of those molecules having passed a single phase III trial. Current plans are to file in Europe for eravacycline, but it's back to phase I for the U.S.

Last share offering, 3/15, was at $35.

Current shares (1/28/16) are going for $5.18.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
80Bullish crossover in MACD and Stochastic oscillator. Looking for breakout at 3.Alejandroo Green-August 6
79I never take my due from class action suits. Last one I participated in was Elascaram(o)uche-July 31
78Yup. I'd be more interested in this for its remaining early stage programs,tuck-February 15
77When it happens twice in 18 months it's hard to make the argument that managHardToFind-February 15
76Here’s What’s Moving Tetraphase Tetraphase Pharmaceuticals, Inc. ( NASDAQ:TTPH)HardToFind-February 14
75So with the Eravacycline program presumably dead, does the remaining pipe look ctuck-February 13
74Sadly, every poorly managed public company will do the same. Only the well managHardToFind-January 23
73What would it take for someone on the Board to say..... "No, no, no, no....scaram(o)uche-January 23 What wouscaram(o)uche2January 23
71Motley Fool article that includes a favorable discussion of TTPH: finance.yahooHardToFind-January 16
70From 200 to 250. Twice a day.gcrispin-12/21/2017
69What was the dosage change? Did they say?HardToFind-12/20/2017
68Thanks. Also a higher dosage. Obviously didn’t do enough testing the first tigcrispin-12/20/2017
67I gather from the 14 Dec 2017 BMO presentation, it seems as though the new oralHardToFind-12/18/2017
66The Latest Press Release On Oral Dosing (11/2/2017): Presented data at IDWeek 2HardToFind-11/5/2017
65Good to know the chatter, thanks.scaram(o)uche-10/9/2017
64...suggesting compliance would be difficult with TID dosing. Not sure how that wHardToFind-10/5/2017
63Saw a tweet concerned with food effect, suggesting compliance would be difficulttuck-10/5/2017 Show you how important the oral has always been to this stock.gcrispin110/4/2017
61Looks like there is a route forward, with modest development time frames. 80%scaram(o)uche-10/4/2017
60Gotcha. Plazomicin is my interest here. Building a modest position in AKAO. Setuck-9/20/2017
59Omadacycline is a tetracycline. So, yes, I watch it as a direct competitor, marscaram(o)uche-9/20/2017
58targets the 30S subunit of the bacterial ribosome. Actually, so do the efforts ftuck-9/19/2017
57Competing program . . . It is my understanding that 271 targets the 30Stuck-9/19/2017
56TTPH started to move up after news came out that Paratek Pharma was putting the gcrispin-8/27/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.